skip to Main Content
Provider Portal
Generic selectors
Exact matches only
Search in title
Search in content

CIRCULOGENE presented plasma PD-L1 data at the American Society for Radiation Oncology (ASTRO) / American Society of Clinical Oncology (ASCO) Multidisciplinary Thoracic Cancers Symposium

FOR IMMEDIATE RELEASE CIRCULOGENE presented plasma PD-L1 data at the American Society for Radiation Oncology (ASTRO) / American Society of Clinical Oncology (ASCO) Multidisciplinary Thoracic Cancers Symposium Liquid PD-L1 data demonstrates clinical utility in lung cancer patients BIRMINGHAM, Ala. and Pensacola, Fla. (December 2, 2021) – CIRCULOGENE, an innovative medical technology company transforming…

CIRCULOGENE Announces Lab Expansion in Florida

FOR IMMEDIATE RELEASE CIRCULOGENE Announces Lab Expansion in Florida Liquid Biopsy Company Laboratory Operations Are Growing in Pensacola  BIRMINGHAM, Ala. and Pensacola, Fla. (October 14, 2021) – CIRCULOGENE, an innovative medical technology company transforming precision medicine through the rapid delivery of actionable results, and the only company in the world with a liquid…

CIRCULOGENE Announces Issuance of U.S. Patent for Method of Preparing Cell-Free Nucleic Acid Molecules by In Situ Amplification

Issued patent recognizes CIRCULOGENE’s novel method of enriching cfDNA without DNA isolation, extraction or purification, enabling “in situ” genetic manipulation of biofluid samples. BIRMINGHAM, Ala. – CIRCULOGENE, an innovative molecular diagnostics company transforming precision medicine through the rapid delivery of actionable results, announced today that the United States Patent and…

Biological Fragmentation of Circulating Cell-free DNA Alters Genetic Representation

 Current Trends in Clinical & Medical Sciences  Chen Hsiung Yeh* Circulogene Theranostics, Birmingham, USA Received Date: January 24, 2020 Published Date: January 29, 2020   Biological Fragmentation of Circulating Cell-free DNA Alters Genetic Representation Click here to download full pdf  High-throughput sequencing of circulating cell-free DNA (cfDNA) as liquid biopsy has revolutionized tumor genome…

CIRCULOGENE – Subcontractor to U.S. Department of Defense Research Award – to Develop Liquid Biopsy Markers for Traumatic Brain Injury

$1.5 Million grant to The Geneva Foundation will use CIRCULOGENE’s liquid biopsy to quickly ID and accurately quantify organ-specific injury markers for improved treatment and survival in severely wounded military and civilian personnel. BIRMINGHAM, Ala.–(BUSINESS WIRE)– CIRCULOGENE molecular diagnostics laboratory, a subcontractor to The Geneva Foundation (Geneva), which has been awarded a $1.5 million…

CIRCULOGENE Molecular Diagnostics Laboratory Receives College of American Pathologists (CAP) Accreditation

 BIRMINGHAM, Ala. – CIRCULOGENE, advancing precision medicine through personalized molecular genetics testing, announced today that its molecular diagnostics laboratory has received College of American Pathologists (CAP) accreditation based on a recent on-site inspection as part of CAP’s Accreditation Programs. The CAP accreditation – and the Clinical Laboratory Improvement Amendments (CLIA) certification…

Back To Top